Details of the Drug Combination

General Information of Drug Combination (ID: DCGY5R1)

• Drug Combination Name: IMD-0354 + GDC-0084
• Indication: Hodgkin lymphoma; Status: Investigative [1]
• Component Drugs:
  IMD-0354 (DMOFSLE): Small molecular drug
  GDC-0084 (DMA9SEY): N.A.
• High-throughput Screening Result:
  Testing Cell Line: L-1236
  Zero Interaction Potency (ZIP) Score: 14.685
  Bliss Independence Score: 16.326
  Loewe Additivity Score: 4.282
  LHighest Single Agent (HSA) Score: 16.562

Molecular Interaction Atlas of This Drug Combination

Indication(s) of IMD-0354

Disease Entry	ICD 11	Status	REF
Acne vulgaris	ED80	Phase 1	[2]

IMD-0354 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Inhibitor of nuclear factor kappa-B kinase beta (IKKB)	TTJ3E9X	IKKB_HUMAN	Inhibitor	[4]

Indication(s) of GDC-0084

Disease Entry	ICD 11	Status	REF
Glioblastoma of brain	2A00.00	Phase 2	[3]

GDC-0084 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
PI3-kinase gamma (PIK3CG)	TTHBTOP	PK3CG_HUMAN	Inhibitor	[5]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] Activation of histamine H4 receptor inhibits TNFalpha/IMD-0354-induced apoptosis in human salivary NS-SV-AC cells. Apoptosis. 2014 Dec;19(12):1702-11.
• [3] ClinicalTrials.gov (NCT03522298) Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma. U.S. National Institutes of Health.
• [4] I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15.
• [5] Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829.